Skip to main content
TipRanks
Go Ultimate75% OFF

NovoCure (NVCR) Stock Statistics & Valuation Metrics

1,591 Followers

Total Valuation

NovoCure has a market cap or net worth of $1.30B. The enterprise value is $1.62B.

Market Cap
$1.30B
Enterprise Value
$1.62B

Share Statistics

NovoCure has 116,915,960 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
116,915,960
Owned by Insiders
2.70%
Owned by Institutions
65.28%

Financial Efficiency

NovoCure’s return on equity (ROE) is -0.40 and return on invested capital (ROIC) is -25.94%.

Return on Equity (ROE)
-0.40
Return on Assets (ROA)
-0.17
Return on Invested Capital (ROIC)
-25.94%
Return on Capital Employed (ROCE)
-0.26
Revenue Per Employee
408.32K
Profits Per Employee
-84.88K
Employee Count
1,605
Asset Turnover
0.81
Inventory Turnover
4.06

Valuation Ratios

The current PE Ratio of NovoCure is -10.46. NovoCure’s PEG ratio is -0.40.

PE Ratio
-10.46
PS Ratio
1.79
PB Ratio
3.69
Price to FCF
-63.85
Price to Operating Cash Flow
360.90
PEG Ratio
-0.40

Income Statement

In the last 12 months, NovoCure had revenue of 655.35M and earned -136.23M in profits. Earnings per share was -1.22.

Revenue
655.35M
Gross Profit
488.47M
Operating Income
-153.80M
Pretax Income
-136.25M
Net Income
-136.23M
EBITDA
-121.60M
Earnings Per Share (EPS)
-1.22

Cash Flow

In the last 12 months, operating cash flow was 3.59M and capital expenditures -23.89M, giving a free cash flow of -20.30M billion.

Operating Cash Flow
3.59M
Free Cash Flow
-20.30M
Free Cash Flow per Share
-0.17

Dividends & Yields

NovoCure pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-1.56%
Earnings Yield
-9.36%

Stock Price Statistics

Beta
1.22
52-Week Price Change
-1.15%
50-Day Moving Average
14.84
200-Day Moving Average
14.83
Relative Strength Index (RSI)
29.88
Average Volume (3m)
1.53M

Important Dates

NovoCure upcoming earnings date is Feb 25, 2027, TBA (Not Confirmed).

Last Earnings Date
Oct 29, 2026
Next Earnings Date
Feb 25, 2027
Ex-Dividend Date
―

Financial Position

NovoCure as a current ratio of 2.90, with Debt / Equity ratio of 85.18%

Current Ratio
2.90
Quick Ratio
2.71
Debt to Market Cap
0.17
Net Debt to EBITDA
-1.53
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, NovoCure has paid -23.00K in taxes.

Income Tax
-23.00K
Effective Tax Rate
0.00

Enterprise Valuation

NovoCure EV to EBITDA ratio is -13.79, with an EV/FCF ratio of -70.81.

EV to Sales
1.98
EV to EBITDA
-13.79
EV to Free Cash Flow
-70.81
EV to Operating Cash Flow
400.69

Balance Sheet

NovoCure has $463.48M in cash and marketable securities with $231.55M in debt, giving a net cash position of $231.93M billion.

Cash & Marketable Securities
$463.48M
Total Debt
$231.55M
Net Cash
$231.93M
Net Cash Per Share
$1.98
Tangible Book Value Per Share
$3.00

Margins

Gross margin is 77.02%, with operating margin of -17.17%, and net profit margin of -16.78%.

Gross Margin
77.02%
Operating Margin
-17.17%
Pretax Margin
-18.00%
Net Profit Margin
-16.78%
EBITDA Margin
-14.37%
EBIT Margin
-16.72%

Analyst Forecast

The average price target for NovoCure is $23.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$23.75
Price Target Upside
113.20% Upside
Analyst Consensus
Strong Buy
Analyst Count
4
Revenue Growth Forecast
12.94%
EPS Growth Forecast
33.87%

Scores

Smart Score
4
AI Score
49